SCHEMBL22275992

SCHEMBL22275992

Nc1ncnc2c1c(-c1cccc3[nH]ncc13)nn2Cc1oc2ccccc2c(=O)c1-c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 15/20 0.49
PIK3CG P48736 6/20 0.49
PIK3R1 P27986 1/20 0.41
CSNK1E P49674 1/20 0.41
SRC P12931 3/20 0.39
PIK3CA P42336 2/20 0.39
PIK3CB P42338 2/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39
HCK P08631 1/20 0.39
KDR P35968 1/20 0.39
MTOR P42345 1/20 0.39
EPHB4 P54760 1/20 0.39
PRKDC P78527 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
PRKD3 O94806 1/20 0.38
PRKD1 Q15139 1/20 0.38
PRKD2 Q9BZL6 1/20 0.38
PIK3C2B O00750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651598 0.93 PIK3CD (0.51) PIK3CDPIK3CGSRCPIK3CAPIK3CB
SCHEMBL10872 0.93 PIK3CD (0.51) PIK3CDPIK3CGSRCPIK3CAPIK3CB
SCHEMBL29651537 0.85 PIK3CD (0.54) PIK3CDPIK3CGPIK3R1CSNK1ESRC
SCHEMBL131144 0.85 PIK3CD (0.54) PIK3CDPIK3CGPIK3R1CSNK1ESRC
SCHEMBL29651604 0.83 PIK3CD (0.67) PIK3CDPIK3CGPIK3R1CSNK1ESRC
SCHEMBL11003 0.83 PIK3CD (0.67) PIK3CDPIK3CGPIK3R1CSNK1ESRC
SCHEMBL30012974 0.83 PIK3CD (0.55) PIK3CDPIK3CGPIK3R1CSNK1ESRC
SCHEMBL11403 0.83 PIK3CD (0.55) PIK3CDPIK3CGPIK3R1CSNK1ESRC
SCHEMBL10593 0.82 PIK3CG (0.55) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C2B
SCHEMBL29651635 0.82 PIK3CG (0.55) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CG 99/4885PIK3R1 95/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CD 103/4885PIK3CG 126/4885PIK3R1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.